What are the recommended dosing, efficacy, safety profile, and monitoring guidelines for centanafadine in treating ADHD in children, adolescents, and adults?

Centanafadine for ADHD: A Novel Triple Reuptake Inhibitor

Centanafadine (Simtriyo®) is a first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) approved for ADHD treatment in adults and adolescents, offering a non-stimulant alternative with demonstrated efficacy and generally favorable tolerability. 1

Mechanism of Action

Centanafadine differs fundamentally from traditional ADHD medications. Unlike amphetamines that actively trigger monoamine release or methylphenidate that selectively blocks dopamine/norepinephrine reuptake, centanafadine inhibits all three monoamine transporters (NET > DAT > SERT) without inducing neurotransmitter release. This mechanism potentially reduces abuse liability, insomnia, and cardiovascular risks compared to traditional stimulants. 1

Dosing Recommendations

Adults (18-55 years)

• Starting dose: 200 mg once daily
• Target dose: 400 mg once daily (given as 200 mg twice daily in sustained-release formulation)
• No titration required in clinical trials 2, 3
• Maximum studied dose: 400 mg/day total

Adolescents (13-17 years)

• Effective dose: 328.8 mg once daily (not titrated)
• The 164.4 mg dose failed to meet primary endpoints 4
• Start directly at 328.8 mg once daily based on trial data

Children (6-12 years)

• High-dose centanafadine showed efficacy in Phase 3 trials 5
• Specific dosing not yet established in provided evidence

Important: Centanafadine dosing differs from traditional stimulants 6 which require gradual titration starting at 5 mg methylphenidate or 2.5 mg amphetamine with weekly increases.

Efficacy Profile

Adults

Two Phase 3 trials demonstrated statistically significant improvements in ADHD symptoms:

• 200 mg/day: Effect sizes -0.28 to -0.37 versus placebo
• 400 mg/day: Effect sizes -0.24 to -0.40 versus placebo
• Mean AISRS total score improvements: -2.74 to -4.47 points versus placebo (p<0.05) 2

Adolescents

• 328.8 mg once daily: Significant improvement in ADHD-RS-5 total score (-18.50 vs -14.15 placebo; p=0.0006)
• Separation from placebo occurred at Week 1 and was maintained throughout 6 weeks 4
• 164.4 mg dose was ineffective

Executive Function and Learning

Beyond core ADHD symptoms, centanafadine demonstrated clinically significant improvements in:

• Executive functioning (T-score changes: -11.3 in children, -13.0 in adolescents vs placebo)
• Learning problems (T-score changes: -8.2 in children, -8.0 in adolescents vs placebo)
• Effects observed as early as Week 1 5

Meta-analysis findings: Pooled effect size of -0.37 (95% CI -0.68 to -0.05) for ADHD symptom reduction across five RCTs 7

Safety and Tolerability

Common Adverse Events

Most frequent (≥5%):

• Decreased appetite (most common)
• Nausea (7.7% in adults, common in adolescents)
• Headache (7.0%)
• Insomnia (8.0% in long-term adult study)
• Diarrhea (7.0%)
• Rash 4, 3

Severity Profile

• Most TEAEs: Mild to moderate severity
• Overall TEAE rate in adolescents: 50.3% at 328.8 mg vs 23.8% placebo 4
• Adult TEAE rate: 61.4% over 52 weeks, mostly mild-moderate 3
• Discontinuation due to TEAEs: 12.3% in long-term adult study 3

Serious Adverse Events

• Incidence: 1.8% in 52-week adult study (none related to centanafadine per investigators) 3
• Three severe events in adolescent trial: liver function test increase, aggression (both on 164.4 mg), and somnolence (placebo) 4
• Abuse potential-related AEs: Low incidence 2

Cardiovascular and Metabolic

• Small dose-dependent increase in TEAE occurrence
• Lower cardiovascular risk profile compared to traditional stimulants due to mechanism 1
• Vital signs monitoring required but less intensive than stimulants

Monitoring Guidelines

Baseline Assessment

Before initiating centanafadine:

• Physical examination with vital signs (blood pressure, pulse)
• Height and weight measurement
• Liver function tests (given one case of LFT elevation) 4
• Screen for comorbidities: anxiety, depression, substance use, tics, sleep disorders 8
• Cardiac history: contraindicated in symptomatic cardiovascular disease, hypertension 6

Ongoing Monitoring

Initial phase (Weeks 1-6):

• Weekly contact (telephone acceptable) to assess efficacy and tolerability
• Systematic assessment of specific side effects: appetite, nausea, headache, sleep, mood changes
• Weight monitoring at each visit

Maintenance phase:

• Monthly appointments until symptoms stabilized 6
• Quarterly vital signs in adults 6
• Annual physical examination with height/weight in children 6
• More frequent visits if: poor response, adherence issues, significant side effects, or comorbid conditions

Efficacy Assessment

• Parent and teacher ratings using validated scales (ADHD-RS-5, Conners 3) 8, 5
• Adolescent/adult self-ratings essential 6
• CGI-S scores for global severity tracking 2
• Target symptom monitoring in home and school/work settings

Clinical Context and Guidelines

Position in Treatment Algorithm

Current ADHD guidelines 8 recommend:

• Ages 6-18: FDA-approved medications (stimulants first-line) with behavioral interventions
• Preschool (4-5 years): Behavioral interventions first; methylphenidate if insufficient response

Centanafadine's role: Provides a non-stimulant option when:

• Stimulants are ineffective or not tolerated
• Concerns about abuse potential exist
• Comorbid anxiety or tics present (traditional contraindications to stimulants) 6
• Cardiovascular concerns limit stimulant use

Contraindications

Based on stimulant guidelines 6 and centanafadine's profile:

• Absolute: Previous sensitivity to centanafadine, active psychotic disorder, MAO inhibitor use
• Relative caution: History of substance abuse (though lower abuse potential than stimulants), hepatic impairment (given LFT case)
• Not contraindicated (unlike stimulant labels): Tics, Tourette's disorder, controlled seizures, anxiety

Advantages Over Traditional Stimulants

• Once-daily dosing (vs multiple daily doses for immediate-release stimulants) 6
• No active neurotransmitter release (lower abuse liability) 1
• Triple mechanism may address broader symptom spectrum including executive function 5
• Lower cardiovascular risk profile 1

Key Clinical Pearls

Dosing pitfall: Unlike stimulants that require gradual titration 6, centanafadine trials used fixed, non-titrated dosing. Start at the effective dose (328.8 mg in adolescents, 400 mg in adults) rather than attempting gradual increases.

Efficacy timeline: Expect symptom improvement by Week 1 4, much faster than some non-stimulants (e.g., atomoxetine requires 4-6 weeks).

Dose-response: In adolescents, the lower dose (164.4 mg) was ineffective—don't underdose. The 328.8 mg dose is necessary for efficacy 4.

Long-term safety: 52-week data in adults shows sustained tolerability with completion rate of 52.1% and continued efficacy (up to 57% improvement in AISRS scores) 3.

Executive function benefits: Centanafadine demonstrated 50-88% greater chance of clinically meaningful improvement in executive functioning compared to placebo—a significant advantage for real-world functional outcomes 5.

Monitoring intensity: While less intensive than stimulants, systematic side effect assessment is critical given the 50% TEAE rate at effective doses. Weight and appetite monitoring are particularly important given decreased appetite as the most common adverse event.